ExodusPoint Capital Management LP Acquires 117,787 Shares of Repligen Co. (NASDAQ:RGEN)

ExodusPoint Capital Management LP lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 122.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 213,718 shares of the biotechnology company's stock after purchasing an additional 117,787 shares during the period. ExodusPoint Capital Management LP owned about 0.38% of Repligen worth $30,763,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Westpac Banking Corp grew its stake in shares of Repligen by 17.9% during the fourth quarter. Westpac Banking Corp now owns 21,725 shares of the biotechnology company's stock valued at $3,127,000 after buying an additional 3,305 shares during the last quarter. Cinctive Capital Management LP grew its position in Repligen by 717.1% during the 4th quarter. Cinctive Capital Management LP now owns 61,398 shares of the biotechnology company's stock worth $8,838,000 after acquiring an additional 53,884 shares during the last quarter. Groupama Asset Managment grew its position in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Alliancebernstein L.P. increased its stake in Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Premier Fund Managers Ltd bought a new stake in Repligen in the fourth quarter valued at approximately $592,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday. Canaccord Genuity Group boosted their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and an average price target of $178.64.

Insider Transactions at Repligen

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Performance

RGEN stock traded down $1.02 during trading on Tuesday, reaching $115.09. The stock had a trading volume of 232,636 shares, compared to its average volume of 689,087. The firm has a market cap of $6.46 billion, a PE ratio of -226.02, a PEG ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock's 50 day moving average is $148.99 and its two-hundred day moving average is $147.41. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.